End to end solution
for genomic diagnostic
Foresee Genomics develops a combined system of molecular biology and bioinformatics. An enabling-technology with the purpose to increase the accuracy of the currently error-prone nanopore-based 4th generation DNA sequencing technology, transforming it into a technology that would be suitable for sensitive diagnostics.
The nanopore sequencing platform is significantly inexpensive in comparison to all other NGS platform.
The combined system of Foresee Genomic and the nanopore sequencer is an end-to-end solution for genomic diagnostics which is accurate and affordable. We give labs the capability to do comprehensive molecular testing in an unprecedented price.
Sensitive accurate diagnosis
Super-low capital investment
Early-stage cancer diagnostic solution
Accessible NGS at the point of care
Combined system of molecular biology and software in order to provide clear diagnosis
Foresee Genomics test replaces the need to forward samples to
costly genomic centers or apply multiple discrete tests.
This results in fast diagnosis, dramatic reduction in necessary infrastructure and equipment, and unprecedented cost effectiveness.
Roi Feingersch, PhD MBA
CEO & FOUNDER
Dr. Feingersch is the founder of Foresee Genomics. He is an expert in the field of Next Generation Sequencing with rich experience in development of genomic diagnostic tests for cancer and genetic diseases. His experience includes developing new diagnostic tools for academic organizations, private diagnostic companies and hospitals. Dr. Feingersch is a Molecular Biologist who graduated from the Technion – Israel Institute of Technology, where he also obtained his postdoctoral fellowship.
Michal Brunwasser Meirom, PhD
Dr. Brunwasser-Meirom is the R&D manager of Foresee Genomics. She is an expert in synthetic biology and gained vast multidisciplinary experience in molecular biology and bioinformatics. Dr. Brunwasser-Meirom completed her PhD studies in Biotechnology, followed by a postdoctoral fellowship in the faculty Medicine both at the Technion – Israel Institute of Technology.
Ronald Udasin, PhD
Dr. Udasin is an experienced molecular biologist with a wide range of experience in cancer research. He completed his PhD in the US in Toxicology in the laboratory of Prof. Jeffrey Laskin at Rutgers University. He then moved on to complete a postdoctoral fellowship in Prof. Aaron Ciechanover’s laboratory at the Faculty of Medicine at the Technion – Israel Institute of Technology.
Yishai Ofran, MD
CHIEF MEDICAL ADVISOR
Dr. Ofran, MD, is the medical expert of Foresee Genomics. He heads the laboratory of genetic and immunology of Leukemia at Rambam Health Care Campus. Dr. Ofran is a senior Hematologist at the Department of Hematology and Bone Marrow Transplantation and a senior lecturer in Hematology at the Rappaport Faculty of Medicine at the Technion – Israel Institute of Technology. Dr. Ofran has actively participated in a wide range of clinical and basic research projects and initiatives. His main research interest is in diagnosis and management of leukemia, focusing on molecular and genetic characterization of leukemic clones and the immunological response to them. Dr. Ofran obtained his medical degree from the Hebrew University of Jerusalem.
Yosef Maruvka, PhD
Data Science & Bioinformatics
Professor Yosef Maruvka, PhD, is the bioinformatics and data science advisor for Foresee Genomics. He is an Assistant Professor at the Technion’s Faculty of Biotechnology and Food Engineering. Dr. Maruvka is an expert in the development of computational tools for analyzing cancer data. In his lab, Dr. Maruvka researches and develops new algorithms and computational tools for analyzing cancer data, with the goal of generating new biological insights and medical diagnostic tools. Dr. Maruvka was a researcher at the Broad Institute and Harvard Medical School, and has published over 50 scientific papers.